Document is current
Any future updates will be listed below
-
Authors
Derosa, Lisa https://orcid.org/0000-0003-0527-2964
Routy, Bertrand https://orcid.org/0000-0003-1955-9149
Thomas, Andrew Maltez https://orcid.org/0000-0001-5789-3354
Iebba, Valerio
Zalcman, Gerard https://orcid.org/0000-0002-0343-9575
Friard, Sylvie
Mazieres, Julien https://orcid.org/0000-0002-5921-7613
Audigier-Valette, Clarisse
Moro-Sibilot, Denis https://orcid.org/0000-0001-6776-8610
Goldwasser, François
Silva, Carolina Alves Costa
Terrisse, Safae
Bonvalet, Melodie https://orcid.org/0000-0003-2692-5338
Scherpereel, Arnaud
Pegliasco, Hervé
Richard, Corentin
Ghiringhelli, François https://orcid.org/0000-0002-5465-8305
Elkrief, Arielle
Desilets, Antoine https://orcid.org/0000-0002-9382-7597
Blanc-Durand, Felix
Cumbo, Fabio
Blanco, Aitor https://orcid.org/0000-0001-7386-5572
Boidot, Romain https://orcid.org/0000-0001-9956-1737
Chevrier, Sandy
Daillère, Romain
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Alla, Laurie
Pons, Nicolas
Le Chatelier, Emmanuelle https://orcid.org/0000-0002-2724-0536
Galleron, Nathalie
Roume, Hugo
Dubuisson, Agathe https://orcid.org/0000-0002-7526-0769
Bouchard, Nicole
Messaoudene, Meriem
Drubay, Damien https://orcid.org/0000-0002-9997-9727
Deutsch, Eric https://orcid.org/0000-0002-8223-3697
Barlesi, Fabrice
Planchard, David
Segata, Nicola https://orcid.org/0000-0002-1583-5794
Martinez, Stéphanie
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Soria, Jean-Charles
Besse, Benjamin
- License Information
-
More Information
Article History
Received: 15 December 2020
Accepted: 6 December 2021
First Online: 3 February 2022
Competing interests
: L. Z. received research contract from Kaleido and Innovate Pharma and Pilege. L. D. has consulted for and had an advisory role for BMS and Sanofi and was supported by Philantropia Fondation Gustave Roussy. G. Z. received a research grant from Fondation Roche, received fees from Roche, MSD, BMS, and Astra-Zeneca, and is consultant for Da Volterra and Inventiva. L.Z and R.D. are the scientific cofounders of Everimmune. E. D. reports grants and personal fees from Roche Genentech, grants from Boehringer, grants from AstraZeneca, grants and personal fees from Merck Serono, grants from BMS, and grants from MSD. P. D. has had consulting and advisory roles for AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, and Samsung, as well as honoraria from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, and Samsung. P. D. ran clinical trials as principal or co-investigator for AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, and Daiichi Sankyo, and has received travel or accommodation expenses from AstraZeneca, Roche, Novartis, prIME Oncology, and Pfizer. F. G. received honoraria from Amgen, Sanofi, Merk Serono, MSD, BMS, and AstraZeneca, had a consultancy or advisory role for Roche and Enterome, and received direct research fundings from Roche, Enterome, AstraZeneca, and Servier and traveling support from Servier, Amgen, and Roche. J. C. S. in the last 2 years has received consultancy fees from Relay Therapeutics and Gritstone and holds shares of Hookipa, Gritstone, AstraZeneca, and Daiichi Sankyo, and was a full time employee for AstraZeneca in 2017–2019. The remaining authors declare no competing interests.
